Kaken Pharmaceutical Co., Ltd.

KKPCF · OTC
Analyze with AI
3/31/2025
3/31/2024
3/31/2023
3/31/2022
Operating Activities
Net Income$19,435$8,025$6,817$13,885
Dep. & Amort.$2,554$2,753$2,568$2,486
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$0$0$0
Change in WC$2,987-$6,359$592-$2,041
Other Non-Cash$4,804-$1,842-$724-$994
Operating Cash Flow$29,780$2,577$9,253$13,336
Investing Activities
PP&E Inv.-$4,138-$1,861-$2,206-$3,257
Net Acquisitions-$15,378$0-$207-$4,975
Inv. Purchases-$400$0-$200$433
Inv. Sales/Matur.$520$516$5$5
Other Inv. Act.-$254-$4,509-$19-$94
Investing Cash Flow-$19,650-$5,854-$2,627-$7,888
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$7,764$0$0$0
Stock Repurch.-$5,935$0-$1,340-$2,414
Dividends Paid-$7,198-$5,657-$5,649-$5,714
Other Fin. Act.$0-$1-$1-$1
Financing Cash Flow-$5,369-$5,658-$6,990-$8,129
Forex Effect$0$0-$1$1
Net Chg. in Cash$4,760-$8,935-$365-$2,680
Supplemental Information
Beg. Cash$65,325$74,260$74,625$77,305
End Cash$70,085$65,325$74,260$74,625
Free Cash Flow$25,388$410$7,047$10,079